免疫介导炎症性疾病中SARS-CoV-2感染:Euro-COVIMID多中心横断面研究
Euro-COVIMID研究在六个欧洲国家招募3136例免疫介导炎症性疾病患者,系统检测SARS-CoV-2血清学并收集临床资料。
要点
- 较高CRP浓度和较多近期疾病 flare 与症状性COVID-19风险增加相关。
核心结论
- 免疫抑制剂在此背景下似乎无害,控制炎症活动在面对大流行时似乎是关键。
研究设计与样本
- 多中心横断面研究,从法国、德国、意大利、葡萄牙、西班牙和英国的六个三级转诊中心招募18岁及以上、临床诊断为类风湿关节炎、中轴脊柱关节炎、系统性红斑狼疮、干燥综合征或巨细胞动脉炎的患者。
- 通过问卷收集人口学、合并症、治疗、近期疾病 flare 及COVID-19症状信息,并系统检测SARS-CoV-2血清学;主要结局为COVID-19的血清学和临床患病率。
临床怎么用
- 在免疫介导炎症性疾病患者中,使用生物制剂未显示增加症状性COVID-19风险,反而与风险降低相关。
- 控制炎症活动(降低CRP、减少疾病 flare)可能有助于降低症状性COVID-19风险。
局限性
- 横断面设计无法确定因果关系。
- 研究期间为2020年6月至12月,结论可能受当时病毒变异和防控措施影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic has raised numerous questions among patients with immune-mediated inflammatory diseases regarding potential reciprocal effects of COVID-19 and their underlying disease, and potential effects of immunomodulatory therapy on outcomes related to COVID-19. The seroprevalence of SARS-CoV-2 and factors associated with symptomatic COVID-19 in patients with immune-mediated inflammatory diseases are still unclear. The Euro-COVIMID study aimed to determine the serological and clinical prevalence of COVID-19 among patients with immune-mediated inflammatory diseases, as well as factors associated with COVID-19 occurrence and the impact of the pandemic in its management. METHODS: In this multicentre cross-sectional study, patients aged 18 years or older with a clinical diagnosis of rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Sjögren's syndrome, or giant cell arteritis were recruited from six tertiary referral centres in France, Germany, Italy, Portugal, Spain, and the UK. Demographics, comorbidities, treatments, and recent disease flares, as well as information on COVID-19 symptoms, were collected through a questionnaire completed by participants. SARS-CoV-2 serology was systematically tested. The main outcome was the serological and clinical prevalence of COVID-19. Factors associated with symptomatic COVID-19 were assessed by multivariable logistic regression, and incidence of recent disease flares, changes in treatments for underlying disease, and the reasons for treatment changes were also assessed. This study is registered with ClinicalTrials.gov, NCT04397237. FINDINGS: Between June 7 and Dec 8, 2020, 3136 patients with an immune-mediated inflammatory disease answered the questionnaire. 3028 patients (median age 58 years [IQR 46-67]; 2239 [73·9%] women and 789 [26·1%] men) with symptomatic COVID-19, serological data, or both were included in analyses. SARS-CoV-2 antibodies were detected in 166 (5·5% [95% CI 4·7-6·4]) of 3018 patients who had serology tests. Symptomatic COVID-19 occurred in 122 (4·0% [95% CI 3·4-4·8]) of 3028 patients, of whom 24 (19·7%) were admitted to hospital and four (3·3%) died. Factors associated with symptomatic COVID-19 were higher concentrations of C-reactive protein (odds ratio 1·18, 95% CI 1·05-1·33; p=0·0063), and higher numbers of recent disease flares (1·27, 1·02-1·58; p=0·030), whereas use of biological therapy was associated with reduced risk (0·51, 0·32-0·82; p=0·0057). At least one disease flare occurred in 654 (21·6%) of 3028 patients. Over the study period, 519 (20·6%) of 2514 patients had treatment changes, of which 125 (24·1%) were due to the pandemic. INTERPRETATION: This study provides key insights into the epidemiology and risk factors of COVID-19 among patients with immune-mediated inflammatory diseases. Overall, immunosuppressants do not seem to be deleterious in this scenario, and the control of inflammatory activity seems to be key when facing the pandemic. FUNDING: Pfizer, Sanofi, Amgen, Galapagos, and Lilly.
引用
- Saadoun D, Vieira M, Vautier M, et al. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. Lancet Rheumatol. 2021. PMID: 33942031. doi:10.1016/S2665-9913(21)00112-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。